Figure 3From: Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against Influenza A M2 proteinEffect of M2-specific scFv-msFc-γ2c antibodies on Influenza-induced morbidity and mortality. Mice were treated with 500 μg of the indicated antibody on day -2, infected with Influenza A virus PR8 on day 0, and body temperature (A), weight (B) and survival (C) were monitored over time.Back to article page